Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm I/II study of ZS801 for hemophilia B
CTR20222717Phase 2Active
- Sponsor
- Zhishan Weixin Biotechnology
- Start
- Nov 2022
- Modality
- Small Molecules, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of ZS801 in hemophilia B (HB), sponsored by Zhishan Weixin Biotechnology. Started Nov 2022; status: active.
02
Drugs
ZS801
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on CTR20222717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222717.